newsfilter
← Latest News
Business Wire·

Astria Therapeutics Enters into Licensing Agreement with Kaken Pharmaceutical to Develop and Commercialize Navenibart for HAE in Japan

-- Up to $32 Million in Upfront and Milestone Payments, Plus Royalties -- -- Kaken Expertise in Commercializing Innovative Therapies Supports Navenibart's Potential to be First-Choice HAE Treatment in Japan -- --